DUBLIN, Oct. 26, 2022 /PRNewswire/ -- The "ADME-Toxicology Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global ADME-Toxicology Testing Market to Reach $12.3 Billion by 2027
In the changed post COVID-19 business landscape, the global market for ADME-Toxicology Testing estimated at US$6 Billion in the year 2020, is projected to reach a revised size of US$12.3 Billion by 2027, growing at a CAGR of 10.9% over the analysis period 2020-2027. Cell Culture, one of the segments analyzed in the report, is projected to record a 13.4% CAGR and reach US$5.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the High Throughput Screening segment is readjusted to a revised 7.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $3 Billion, While China is Forecast to Grow at 15.4% CAGR
The ADME-Toxicology Testing market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$966.9 Million by the year 2027 trailing a CAGR of 15.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 12.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.
Molecular Imaging Segment to Record 9.6% CAGR
In the global Molecular Imaging segment, USA, Canada, Japan, China and Europe will drive the 9.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$974.7 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 79 Featured) -
- Agilent Technologies, Inc.
- Beckman Coulter, Inc.
- BioreclamationIVT, LLC
- CompuDrug International, Inc.
- Cyprotex PLC.
- Eurofins ADME BIOANALYSES SAS
- Molecular Discovery Ltd.
- MultiCASE, Inc.
- PerkinElmer, Inc.
- Pharmaron, Inc.
- Promega Corporation
- Simulations Plus, Inc.
- Taconic Biosciences, Inc.
- Takara Bio Europe AB
- Tecan Group Ltd.
- Thermo Fisher Scientific, Inc.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Increased Need to Check Late-Stage Drug Failures Drive Market Growth
- Steady Increase in Average Drug Development Cost and Efforts to Mitigate Late-Stage Drug Failure Rates Highlights the Role of ADME-Toxicology Testing
- Impact of ADME-Tox Screening on New Drug Discovery
- Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics
- Pharma Industry Renews Focus on Cost Optimization
- China and India: Hot Spots for R&D Investment
- Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge
- Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
- Major Types of Cell-Based HTS Assays for Drug Screening
- Cell-based Assays in HTS and UHTS
- Innovation in Screening Guarantees Success for Drug Discovery Programs
- High-Content Screening (HCS) - An Expanding Technology in Cell-Based Assays
- High Content Screening - Key Application Areas
- HCS Market Ripe with Growth Opportunity
- Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
- 3D Cell Culture Technology to Put a New Spin on In Vitro Cell Analyses
- CDER's DARS 2 - Microphysiological 3D Cell Culture Platforms as Drug Development Tools
- Rising Investment in Proteomics R&D Drive Cell-based Assays Market
- Automated Multiplexing Platforms Present Growth Opportunities
- Automation of Cell-based Assays: A Growing Trend
- In-Silico ADME Emerge as Compelling Drug Discovery & Development Tool
- Advantages of Using In Silico Approaches
- Personalized Treatments & Computational Tools: Intriguing Facets of ADME R&D ADME Pharmacogenomics to Power Personalized Treatments
- In Vitro 3D Organoid Models to Meet ADME-Toxicity Testing Needs
- Limitations of Traditional in vitro Cellular Models
- Organoids Technology - Advanced in vitro 3D Platforms for More Physiologically Relevant Modeling
- Stem Cells Exude Great Potential in Drug Toxicity Testing
- Global Market for Stem Cell-Assays
- Functional Assays: An Effective Way of Predicting Specific Toxic Effects
- GPCR Targets to Drive Growth in Functional Cell Assay Market
- Molecular Imaging and ADME
- Organ-on-a-Chip Technology Gains Momentum in ADME Toxicology Testing
- Technological Advancements in ADME Toxicology Testing
4. GLOBAL MARKET PERSPECTIVE
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/e0pt0i
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
